Efficacy and safety of cemiplimab in cutaneous squamous cell carcinoma on chronic wounds: A French retrospective study

Background: Chronic wounds increase the risk of the development of cutaneous squamous cell carcinoma (SCC), often resulting in poor prognosis in part because of delayed diagnosis. Cemiplimab, an anti-PD-1 agent, is recommended as first-line treatment for metastatic or locally advanced SCC not eligib...

Cijeli opis

Bibliografski detalji

Glavni autori:	M. Antoszczak, E. Maubec, A.-B. Duval-Modeste, A. Jannic, C. Jacobzone-Leveque, R. Lesbazeilles, F. Skowron, D. Solub, J. Ancel, L. Mortier, M. Viguier
Format:	Artigo
Jezik:	Inglês
Izdano:	Elsevier 2024-12-01
Serija:	EJC Skin Cancer
Teme:	Squamous cell carcinoma Immunotherapy Wounds and injuries Leg ulcer
Online pristup:	http://www.sciencedirect.com/science/article/pii/S2772611824002611
Oznake:	Dodaj oznaku Bez oznaka, Budi prvi tko označuje ovaj zapis!